Aptevo Therapeutics Inc. (APVO)

0.9890 -0.1410 (-12.48%) 收市：04:00PM EDT

Aptevo Therapeutics Inc.

2401 4th Avenue
Suite 1050
Seattle, WA 98121
United States
206 838 0500
https://www.aptevotherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 40

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Marvin L. White	President, CEO & Director	841.39k	無	1962
Mr. Jeffrey G. Lamothe CA	Executive VP & COO	722.51k	無	1966
Ms. SoYoung Kwon J.D., LL.M.	Senior VP, General Counsel, Business Development & Corporate Affairs	639.37k	無	1969
Ms. Daphne L. Taylor	Senior VP & CFO	無	無	1966
Dr. Dirk Huebner M.D.	Chief Medical Officer	無	無	1964

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

公司管治

截至 無 止，Aptevo Therapeutics Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。